Covid-19 Impact on Hypertension Drug Market, Global Research Reports 2020-2021
This report covers market size and forecasts of Hypertension Drug, including the following market information:
Major competitors identified in this market include Lupin Limited, Novartis AG, Daiichi - Sankyo, Pfizer Inc, Ranbaxy Laboratories Limited, Sanofi S.A, AstraZeneca Plc, Johnson & Johnson Ltd, Boehringer Ingelheim, Merck & Co., etc.
Based on the Region:
- Global Hypertension Drug Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units)
- Global Hypertension Drug Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units)
- Global Hypertension Drug Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units)
- Global Hypertension Drug Market Size by Company, 2019- 2020 (quarterly data), (US$ Million) & (K Units)
Major competitors identified in this market include Lupin Limited, Novartis AG, Daiichi - Sankyo, Pfizer Inc, Ranbaxy Laboratories Limited, Sanofi S.A, AstraZeneca Plc, Johnson & Johnson Ltd, Boehringer Ingelheim, Merck & Co., etc.
Based on the Region:
- Asia-Pacific (China, Japan, South Korea, India and ASEAN)
- North America (US and Canada)
- Europe (Germany, France, UK and Italy)
- Rest of World (Latin America, Middle East & Africa)
- Calcium Channel Blockers
- Diuretics
- Beta Blockers Vasodilators
- Angiotensin Converting Enzyme Inhibitors
- Alpha Blockers
- Angiotensin Receptor Blockers
- Renin Inhibitors
- Hospital
- Private clinic
- Others
1.1 Research Scope
1.2 Market Segmentation
1.3 Research Objectives
1.4 Research Methodology
1.4.1 Research Process
1.4.2 Data Triangulation
1.4.3 Research Approach
1.4.4 Base Year
1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.5.2 Covid-19 Impact: Commodity Prices Indices
1.5.3 Covid-19 Impact: Global Major Government Policy
1.6 The Covid-19 Impact on Hypertension Drug Industry
1.7 COVID-19 Impact: Hypertension Drug Market Trends
2 GLOBAL HYPERTENSION DRUG QUARTERLY MARKET SIZE ANALYSIS
2.1 Hypertension Drug Business Impact Assessment - COVID-19
2.1.1 Global Hypertension Drug Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
2.1.2 Global Hypertension Drug Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
2.2 Global Hypertension Drug Quarterly Market Size 2020-2021
2.3 COVID-19-Driven Market Dynamics and Factor Analysis
2.3.1 Drivers
2.3.2 Restraints
2.3.3 Opportunities
2.3.4 Challenges
3 QUARTERLY COMPETITIVE ASSESSMENT, 2020
3.1 Global Hypertension Drug Quarterly Market Size by Manufacturers, 2019 VS 2020
3.2 Global Hypertension Drug Factory Price by Manufacturers
3.3 Location of Key Manufacturers Hypertension Drug Manufacturing Factories and Area Served
3.4 Date of Key Manufacturers Enter into Hypertension Drug Market
3.5 Key Manufacturers Hypertension Drug Product Offered
3.6 Mergers & Acquisitions, Expansion Plans
4 IMPACT OF COVID-19 ON HYPERTENSION DRUG SEGMENTS, BY TYPE
4.1 Introduction
1.4.1 Calcium Channel Blockers
1.4.2 Diuretics
1.4.3 Beta Blockers Vasodilators
1.4.4 Angiotensin Converting Enzyme Inhibitors
1.4.5 Alpha Blockers
1.4.6 Angiotensin Receptor Blockers
1.4.7 Renin Inhibitors
4.2 By Type, Global Hypertension Drug Market Size, 2019-2021
4.2.1 By Type, Global Hypertension Drug Market Size by Type, 2020-2021
4.2.2 By Type, Global Hypertension Drug Price, 2020-2021
5 IMPACT OF COVID-19 ON HYPERTENSION DRUG SEGMENTS, BY APPLICATION
5.1 Overview
5.5.1 Hospital
5.5.2 Private clinic
5.5.3 Others
5.2 By Application, Global Hypertension Drug Market Size, 2019-2021
5.2.1 By Application, Global Hypertension Drug Market Size by Application, 2019-2021
5.2.2 By Application, Global Hypertension Drug Price, 2020-2021
6 GEOGRAPHIC ANALYSIS
6.1 Introduction
6.2 North America
6.2.1 Macroeconomic Indicators of US
6.2.2 US
6.2.3 Canada
6.3 Europe
6.3.1 Macroeconomic Indicators of Europe
6.3.2 Germany
6.3.3 France
6.3.4 UK
6.3.5 Italy
6.4 Asia-Pacific
6.4.1 Macroeconomic Indicators of Asia-Pacific
6.4.2 China
6.4.3 Japan
6.4.4 South Korea
6.4.5 India
6.4.6 ASEAN
6.5 Rest of World
6.5.1 Latin America
6.5.2 Middle East and Africa
7 COMPANY PROFILES
7.1 Lupin Limited
7.1.1 Lupin Limited Business Overview
7.1.2 Lupin Limited Hypertension Drug Quarterly Production and Revenue, 2020
7.1.3 Lupin Limited Hypertension Drug Product Introduction
7.1.4 Lupin Limited Response to COVID-19 and Related Developments
7.2 Novartis AG
7.2.1 Novartis AG Business Overview
7.2.2 Novartis AG Hypertension Drug Quarterly Production and Revenue, 2020
7.2.3 Novartis AG Hypertension Drug Product Introduction
7.2.4 Novartis AG Response to COVID-19 and Related Developments
7.3 Daiichi - Sankyo
7.3.1 Daiichi - Sankyo Business Overview
7.3.2 Daiichi - Sankyo Hypertension Drug Quarterly Production and Revenue, 2020
7.3.3 Daiichi - Sankyo Hypertension Drug Product Introduction
7.3.4 Daiichi - Sankyo Response to COVID-19 and Related Developments
7.4 Pfizer Inc
7.4.1 Pfizer Inc Business Overview
7.4.2 Pfizer Inc Hypertension Drug Quarterly Production and Revenue, 2020
7.4.3 Pfizer Inc Hypertension Drug Product Introduction
7.4.4 Pfizer Inc Response to COVID-19 and Related Developments
7.5 Ranbaxy Laboratories Limited
7.5.1 Ranbaxy Laboratories Limited Business Overview
7.5.2 Ranbaxy Laboratories Limited Hypertension Drug Quarterly Production and Revenue, 2020
7.5.3 Ranbaxy Laboratories Limited Hypertension Drug Product Introduction
7.5.4 Ranbaxy Laboratories Limited Response to COVID-19 and Related Developments
7.6 Sanofi S.A
7.6.1 Sanofi S.A Business Overview
7.6.2 Sanofi S.A Hypertension Drug Quarterly Production and Revenue, 2020
7.6.3 Sanofi S.A Hypertension Drug Product Introduction
7.6.4 Sanofi S.A Response to COVID-19 and Related Developments
7.7 AstraZeneca Plc
7.7.1 AstraZeneca Plc Business Overview
7.7.2 AstraZeneca Plc Hypertension Drug Quarterly Production and Revenue, 2020
7.7.3 AstraZeneca Plc Hypertension Drug Product Introduction
7.7.4 AstraZeneca Plc Response to COVID-19 and Related Developments
7.8 Johnson & Johnson Ltd
7.8.1 Johnson & Johnson Ltd Business Overview
7.8.2 Johnson & Johnson Ltd Hypertension Drug Quarterly Production and Revenue, 2020
7.8.3 Johnson & Johnson Ltd Hypertension Drug Product Introduction
7.8.4 Johnson & Johnson Ltd Response to COVID-19 and Related Developments
7.9 Boehringer Ingelheim
7.9.1 Boehringer Ingelheim Business Overview
7.9.2 Boehringer Ingelheim Hypertension Drug Quarterly Production and Revenue, 2020
7.9.3 Boehringer Ingelheim Hypertension Drug Product Introduction
7.9.4 Boehringer Ingelheim Response to COVID-19 and Related Developments
7.10 Merck & Co.
7.10.1 Merck & Co. Business Overview
7.10.2 Merck & Co. Hypertension Drug Quarterly Production and Revenue, 2020
7.10.3 Merck & Co. Hypertension Drug Product Introduction
7.10.4 Merck & Co. Response to COVID-19 and Related Developments
8 SUPPLY CHAIN AND SALES CHANNELS ANALYSIS
8.1 Hypertension Drug Supply Chain Analysis
8.1.1 Hypertension Drug Supply Chain Analysis
8.1.2 Covid-19 Impact on Hypertension Drug Supply Chain
8.2 Distribution Channels Analysis
8.2.1 Hypertension Drug Distribution Channels
8.2.2 Covid-19 Impact on Hypertension Drug Distribution Channels
8.2.3 Hypertension Drug Distributors
8.3 Hypertension Drug Customers
9 KEY FINDINGS
10 APPENDIX
10.1 About Us
10.2 Disclaimer
1.2 Market Segmentation
1.3 Research Objectives
1.4 Research Methodology
1.4.1 Research Process
1.4.2 Data Triangulation
1.4.3 Research Approach
1.4.4 Base Year
1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.5.2 Covid-19 Impact: Commodity Prices Indices
1.5.3 Covid-19 Impact: Global Major Government Policy
1.6 The Covid-19 Impact on Hypertension Drug Industry
1.7 COVID-19 Impact: Hypertension Drug Market Trends
2 GLOBAL HYPERTENSION DRUG QUARTERLY MARKET SIZE ANALYSIS
2.1 Hypertension Drug Business Impact Assessment - COVID-19
2.1.1 Global Hypertension Drug Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
2.1.2 Global Hypertension Drug Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
2.2 Global Hypertension Drug Quarterly Market Size 2020-2021
2.3 COVID-19-Driven Market Dynamics and Factor Analysis
2.3.1 Drivers
2.3.2 Restraints
2.3.3 Opportunities
2.3.4 Challenges
3 QUARTERLY COMPETITIVE ASSESSMENT, 2020
3.1 Global Hypertension Drug Quarterly Market Size by Manufacturers, 2019 VS 2020
3.2 Global Hypertension Drug Factory Price by Manufacturers
3.3 Location of Key Manufacturers Hypertension Drug Manufacturing Factories and Area Served
3.4 Date of Key Manufacturers Enter into Hypertension Drug Market
3.5 Key Manufacturers Hypertension Drug Product Offered
3.6 Mergers & Acquisitions, Expansion Plans
4 IMPACT OF COVID-19 ON HYPERTENSION DRUG SEGMENTS, BY TYPE
4.1 Introduction
1.4.1 Calcium Channel Blockers
1.4.2 Diuretics
1.4.3 Beta Blockers Vasodilators
1.4.4 Angiotensin Converting Enzyme Inhibitors
1.4.5 Alpha Blockers
1.4.6 Angiotensin Receptor Blockers
1.4.7 Renin Inhibitors
4.2 By Type, Global Hypertension Drug Market Size, 2019-2021
4.2.1 By Type, Global Hypertension Drug Market Size by Type, 2020-2021
4.2.2 By Type, Global Hypertension Drug Price, 2020-2021
5 IMPACT OF COVID-19 ON HYPERTENSION DRUG SEGMENTS, BY APPLICATION
5.1 Overview
5.5.1 Hospital
5.5.2 Private clinic
5.5.3 Others
5.2 By Application, Global Hypertension Drug Market Size, 2019-2021
5.2.1 By Application, Global Hypertension Drug Market Size by Application, 2019-2021
5.2.2 By Application, Global Hypertension Drug Price, 2020-2021
6 GEOGRAPHIC ANALYSIS
6.1 Introduction
6.2 North America
6.2.1 Macroeconomic Indicators of US
6.2.2 US
6.2.3 Canada
6.3 Europe
6.3.1 Macroeconomic Indicators of Europe
6.3.2 Germany
6.3.3 France
6.3.4 UK
6.3.5 Italy
6.4 Asia-Pacific
6.4.1 Macroeconomic Indicators of Asia-Pacific
6.4.2 China
6.4.3 Japan
6.4.4 South Korea
6.4.5 India
6.4.6 ASEAN
6.5 Rest of World
6.5.1 Latin America
6.5.2 Middle East and Africa
7 COMPANY PROFILES
7.1 Lupin Limited
7.1.1 Lupin Limited Business Overview
7.1.2 Lupin Limited Hypertension Drug Quarterly Production and Revenue, 2020
7.1.3 Lupin Limited Hypertension Drug Product Introduction
7.1.4 Lupin Limited Response to COVID-19 and Related Developments
7.2 Novartis AG
7.2.1 Novartis AG Business Overview
7.2.2 Novartis AG Hypertension Drug Quarterly Production and Revenue, 2020
7.2.3 Novartis AG Hypertension Drug Product Introduction
7.2.4 Novartis AG Response to COVID-19 and Related Developments
7.3 Daiichi - Sankyo
7.3.1 Daiichi - Sankyo Business Overview
7.3.2 Daiichi - Sankyo Hypertension Drug Quarterly Production and Revenue, 2020
7.3.3 Daiichi - Sankyo Hypertension Drug Product Introduction
7.3.4 Daiichi - Sankyo Response to COVID-19 and Related Developments
7.4 Pfizer Inc
7.4.1 Pfizer Inc Business Overview
7.4.2 Pfizer Inc Hypertension Drug Quarterly Production and Revenue, 2020
7.4.3 Pfizer Inc Hypertension Drug Product Introduction
7.4.4 Pfizer Inc Response to COVID-19 and Related Developments
7.5 Ranbaxy Laboratories Limited
7.5.1 Ranbaxy Laboratories Limited Business Overview
7.5.2 Ranbaxy Laboratories Limited Hypertension Drug Quarterly Production and Revenue, 2020
7.5.3 Ranbaxy Laboratories Limited Hypertension Drug Product Introduction
7.5.4 Ranbaxy Laboratories Limited Response to COVID-19 and Related Developments
7.6 Sanofi S.A
7.6.1 Sanofi S.A Business Overview
7.6.2 Sanofi S.A Hypertension Drug Quarterly Production and Revenue, 2020
7.6.3 Sanofi S.A Hypertension Drug Product Introduction
7.6.4 Sanofi S.A Response to COVID-19 and Related Developments
7.7 AstraZeneca Plc
7.7.1 AstraZeneca Plc Business Overview
7.7.2 AstraZeneca Plc Hypertension Drug Quarterly Production and Revenue, 2020
7.7.3 AstraZeneca Plc Hypertension Drug Product Introduction
7.7.4 AstraZeneca Plc Response to COVID-19 and Related Developments
7.8 Johnson & Johnson Ltd
7.8.1 Johnson & Johnson Ltd Business Overview
7.8.2 Johnson & Johnson Ltd Hypertension Drug Quarterly Production and Revenue, 2020
7.8.3 Johnson & Johnson Ltd Hypertension Drug Product Introduction
7.8.4 Johnson & Johnson Ltd Response to COVID-19 and Related Developments
7.9 Boehringer Ingelheim
7.9.1 Boehringer Ingelheim Business Overview
7.9.2 Boehringer Ingelheim Hypertension Drug Quarterly Production and Revenue, 2020
7.9.3 Boehringer Ingelheim Hypertension Drug Product Introduction
7.9.4 Boehringer Ingelheim Response to COVID-19 and Related Developments
7.10 Merck & Co.
7.10.1 Merck & Co. Business Overview
7.10.2 Merck & Co. Hypertension Drug Quarterly Production and Revenue, 2020
7.10.3 Merck & Co. Hypertension Drug Product Introduction
7.10.4 Merck & Co. Response to COVID-19 and Related Developments
8 SUPPLY CHAIN AND SALES CHANNELS ANALYSIS
8.1 Hypertension Drug Supply Chain Analysis
8.1.1 Hypertension Drug Supply Chain Analysis
8.1.2 Covid-19 Impact on Hypertension Drug Supply Chain
8.2 Distribution Channels Analysis
8.2.1 Hypertension Drug Distribution Channels
8.2.2 Covid-19 Impact on Hypertension Drug Distribution Channels
8.2.3 Hypertension Drug Distributors
8.3 Hypertension Drug Customers
9 KEY FINDINGS
10 APPENDIX
10.1 About Us
10.2 Disclaimer
LIST OF TABLES
Table 1. Overview of the World Economic Outlook Projections
Table 2. Summary of World Real per Capita Output (Annual percent change; in international currency at purchasing power parity)
Table 3. European Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 4. Asian and Pacific Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 5. Western Hemisphere Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 6. Middle Eastern and Central Asian Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 7. Covid-19 Impact: Global Major Government Policy
Table 8. The Covid-19 Impact on Hypertension Drug Assessment
Table 9. COVID-19 Impact: Hypertension Drug Market Trends
Table 10. COVID-19 Impact Global Hypertension Drug Market Size
Table 11. Global Hypertension Drug Market Size Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026 (K Units)
Table 12. Global Hypertension Drug Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026, (USD/Unit)
Table 13. Global Hypertension Drug Quarterly Market Size, 2020 (US$ Million) & (K Units)
Table 14. Global Hypertension Drug Market Size, Pre-COVID-19 and Post- COVID-19 Quarterly Comparison, 2020-2021 (US$ Million)
Table 15. Global Hypertension Drug Market Size, Pre-COVID-19 and Post- COVID-19 Quarterly Comparison, 2020-2021 (K Units)
Table 16. Global Hypertension Drug Market Growth Drivers
Table 17. Global Hypertension Drug Market Restraints
Table 18. Global Hypertension Drug Market Opportunities
Table 19. Global Hypertension Drug Market Challenges
Table 20. Key Manufacturers Hypertension Drug Quarterly Revenue, 2019 VS 2020 (US$ Million)
Table 21. Top Manufacturers, Hypertension Drug Market Size, 2019 (K Units) & (US$ Million)
Table 22. Hypertension Drug Factory Price by Manufacturers 2020 (USD/Unit)
Table 23. Location of Key Manufacturers Hypertension Drug Manufacturing Plants
Table 24. Key Manufacturers Hypertension Drug Market Served
Table 25. Date of Key Manufacturers Enter into Hypertension Drug Market
Table 26. Key Manufacturers Hypertension Drug Product Type
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Hypertension Drug Market Size by Type, 2020, (US$ Million)
Table 29. Global Hypertension Drug Market Size by Type, 2020 (K Units)
Table 30. Global Hypertension Drug Price: by Type, 2020-2021 (USD/Unit)
Table 31. Global Hypertension Drug Market Size by Application: 2020-2021 (US$ Million)
Table 32. Global Hypertension Drug Market Size by Application, 2020-2021 (K Units)
Table 33. Global Hypertension Drug Price: by Application, 2020-2021 (USD/Unit)
Table 34. Global Hypertension Drug Market Size by Region, 2019-2021 (US$ Million)
Table 35. Global Hypertension Drug Market Size by Region, 2019-2021 (K Units)
Table 36. By Country, North America Hypertension Drug Market Size, 2019-2021 (US$ Million)
Table 37. By Country, North America Hypertension Drug Market Size, 2019-2021 (K Units)
Table 38. US Hypertension Drug Market Size, 2019-2021 (US$ Million) & (K Units)
Table 39. Canada Hypertension Drug Market Size, 2019-2021 (US$ Million) & (K Units)
Table 40. Macroeconomic Indicators of Europe (Germany, France, UK and Italy)
Table 41. By Country, Europe Hypertension Drug Market Size, 2019-2021 (US$ Million)
Table 42. By Country, Europe Hypertension Drug Market Size, 2019-2021 (K Units)
Table 43. Germany Hypertension Drug Market Size, 2019-2021 (US$ Million) & (K Units)
Table 44. France Hypertension Drug Market Size, 2019-2021 (US$ Million) & (K Units)
Table 45. UK Hypertension Drug Market Size, 2019-2021 (US$ Million) & (K Units)
Table 46. Italy Hypertension Drug Market Size, 2019-2021 (US$ Million) & (K Units)
Table 47. Macroeconomic Indicators of Asia-Pacific (China, Japan, South Korea, India and ASEAN)
Table 48. By Region, Asia-Pacific Hypertension Drug Market Size, 2019-2021 (US$ Million)
Table 49. By Region, Asia-Pacific Hypertension Drug Market Size, 2019-2021 (K Units)
Table 50. China Hypertension Drug Market Size, 2019-2021 (US$ Million) & (K Units)
Table 51. Japan Hypertension Drug Market Size, 2019-2021 (US$ Million) & (K Units)
Table 52. South Korea Hypertension Drug Market Size, 2019-2021 (US$ Million) & (K Units)
Table 53. India Hypertension Drug Market Size, 2019-2021 (US$ Million) & (K Units)
Table 54. ASEAN Hypertension Drug Market Size, 2019-2021 (US$ Million) & (K Units)
Table 55. Latin America Hypertension Drug Market Size, 2019-2021 (US$ Million) & (K Units)
Table 56. Middle East and Africa Hypertension Drug Market Size, 2019-2021 (US$ Million) & (K Units)
Table 57. Lupin Limited Business Overview
Table 58. Lupin Limited Hypertension Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 59. Lupin Limited Hypertension Drug Product
Table 60. Lupin Limited Response to COVID-19 and Related Developments
Table 61. Novartis AG Business Overview
Table 62. Novartis AG Hypertension Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 63. Novartis AG Hypertension Drug Product
Table 64. Novartis AG Response to COVID-19 and Related Developments
Table 65. Daiichi - Sankyo Business Overview
Table 66. Daiichi - Sankyo Hypertension Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 67. Daiichi - Sankyo Hypertension Drug Product
Table 68. Daiichi - Sankyo Response to COVID-19 and Related Developments
Table 69. Pfizer Inc Business Overview
Table 70. Pfizer Inc Hypertension Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 71. Pfizer Inc Hypertension Drug Product
Table 72. Pfizer Inc Response to COVID-19 and Related Developments
Table 73. Ranbaxy Laboratories Limited Business Overview
Table 74. Ranbaxy Laboratories Limited Hypertension Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 75. Ranbaxy Laboratories Limited Hypertension Drug Product
Table 76. Ranbaxy Laboratories Limited Response to COVID-19 and Related Developments
Table 77. Sanofi S.A Business Overview
Table 78. Sanofi S.A Hypertension Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 79. Sanofi S.A Hypertension Drug Product
Table 80. Sanofi S.A Response to COVID-19 and Related Developments
Table 81. AstraZeneca Plc Business Overview
Table 82. AstraZeneca Plc Hypertension Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 83. AstraZeneca Plc Hypertension Drug Product
Table 84. AstraZeneca Plc Response to COVID-19 and Related Developments
Table 85. Johnson & Johnson Ltd Business Overview
Table 86. Johnson & Johnson Ltd Hypertension Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 87. Johnson & Johnson Ltd Hypertension Drug Product
Table 88. Johnson & Johnson Ltd Response to COVID-19 and Related Developments
Table 89. Boehringer Ingelheim Business Overview
Table 90. Boehringer Ingelheim Hypertension Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 91. Boehringer Ingelheim Hypertension Drug Product
Table 92. Boehringer Ingelheim Response to COVID-19 and Related Developments
Table 93. Merck & Co. Business Overview
Table 94. Merck & Co. Hypertension Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 95. Merck & Co. Hypertension Drug Product
Table 96. Merck & Co. Response to COVID-19 and Related Developments
Table 97. Hypertension Drug Distributors List
Table 98. Hypertension Drug Customers List
Table 99. Covid-19 Impact on Hypertension Drug Customers
Table 1. Overview of the World Economic Outlook Projections
Table 2. Summary of World Real per Capita Output (Annual percent change; in international currency at purchasing power parity)
Table 3. European Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 4. Asian and Pacific Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 5. Western Hemisphere Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 6. Middle Eastern and Central Asian Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 7. Covid-19 Impact: Global Major Government Policy
Table 8. The Covid-19 Impact on Hypertension Drug Assessment
Table 9. COVID-19 Impact: Hypertension Drug Market Trends
Table 10. COVID-19 Impact Global Hypertension Drug Market Size
Table 11. Global Hypertension Drug Market Size Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026 (K Units)
Table 12. Global Hypertension Drug Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026, (USD/Unit)
Table 13. Global Hypertension Drug Quarterly Market Size, 2020 (US$ Million) & (K Units)
Table 14. Global Hypertension Drug Market Size, Pre-COVID-19 and Post- COVID-19 Quarterly Comparison, 2020-2021 (US$ Million)
Table 15. Global Hypertension Drug Market Size, Pre-COVID-19 and Post- COVID-19 Quarterly Comparison, 2020-2021 (K Units)
Table 16. Global Hypertension Drug Market Growth Drivers
Table 17. Global Hypertension Drug Market Restraints
Table 18. Global Hypertension Drug Market Opportunities
Table 19. Global Hypertension Drug Market Challenges
Table 20. Key Manufacturers Hypertension Drug Quarterly Revenue, 2019 VS 2020 (US$ Million)
Table 21. Top Manufacturers, Hypertension Drug Market Size, 2019 (K Units) & (US$ Million)
Table 22. Hypertension Drug Factory Price by Manufacturers 2020 (USD/Unit)
Table 23. Location of Key Manufacturers Hypertension Drug Manufacturing Plants
Table 24. Key Manufacturers Hypertension Drug Market Served
Table 25. Date of Key Manufacturers Enter into Hypertension Drug Market
Table 26. Key Manufacturers Hypertension Drug Product Type
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Hypertension Drug Market Size by Type, 2020, (US$ Million)
Table 29. Global Hypertension Drug Market Size by Type, 2020 (K Units)
Table 30. Global Hypertension Drug Price: by Type, 2020-2021 (USD/Unit)
Table 31. Global Hypertension Drug Market Size by Application: 2020-2021 (US$ Million)
Table 32. Global Hypertension Drug Market Size by Application, 2020-2021 (K Units)
Table 33. Global Hypertension Drug Price: by Application, 2020-2021 (USD/Unit)
Table 34. Global Hypertension Drug Market Size by Region, 2019-2021 (US$ Million)
Table 35. Global Hypertension Drug Market Size by Region, 2019-2021 (K Units)
Table 36. By Country, North America Hypertension Drug Market Size, 2019-2021 (US$ Million)
Table 37. By Country, North America Hypertension Drug Market Size, 2019-2021 (K Units)
Table 38. US Hypertension Drug Market Size, 2019-2021 (US$ Million) & (K Units)
Table 39. Canada Hypertension Drug Market Size, 2019-2021 (US$ Million) & (K Units)
Table 40. Macroeconomic Indicators of Europe (Germany, France, UK and Italy)
Table 41. By Country, Europe Hypertension Drug Market Size, 2019-2021 (US$ Million)
Table 42. By Country, Europe Hypertension Drug Market Size, 2019-2021 (K Units)
Table 43. Germany Hypertension Drug Market Size, 2019-2021 (US$ Million) & (K Units)
Table 44. France Hypertension Drug Market Size, 2019-2021 (US$ Million) & (K Units)
Table 45. UK Hypertension Drug Market Size, 2019-2021 (US$ Million) & (K Units)
Table 46. Italy Hypertension Drug Market Size, 2019-2021 (US$ Million) & (K Units)
Table 47. Macroeconomic Indicators of Asia-Pacific (China, Japan, South Korea, India and ASEAN)
Table 48. By Region, Asia-Pacific Hypertension Drug Market Size, 2019-2021 (US$ Million)
Table 49. By Region, Asia-Pacific Hypertension Drug Market Size, 2019-2021 (K Units)
Table 50. China Hypertension Drug Market Size, 2019-2021 (US$ Million) & (K Units)
Table 51. Japan Hypertension Drug Market Size, 2019-2021 (US$ Million) & (K Units)
Table 52. South Korea Hypertension Drug Market Size, 2019-2021 (US$ Million) & (K Units)
Table 53. India Hypertension Drug Market Size, 2019-2021 (US$ Million) & (K Units)
Table 54. ASEAN Hypertension Drug Market Size, 2019-2021 (US$ Million) & (K Units)
Table 55. Latin America Hypertension Drug Market Size, 2019-2021 (US$ Million) & (K Units)
Table 56. Middle East and Africa Hypertension Drug Market Size, 2019-2021 (US$ Million) & (K Units)
Table 57. Lupin Limited Business Overview
Table 58. Lupin Limited Hypertension Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 59. Lupin Limited Hypertension Drug Product
Table 60. Lupin Limited Response to COVID-19 and Related Developments
Table 61. Novartis AG Business Overview
Table 62. Novartis AG Hypertension Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 63. Novartis AG Hypertension Drug Product
Table 64. Novartis AG Response to COVID-19 and Related Developments
Table 65. Daiichi - Sankyo Business Overview
Table 66. Daiichi - Sankyo Hypertension Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 67. Daiichi - Sankyo Hypertension Drug Product
Table 68. Daiichi - Sankyo Response to COVID-19 and Related Developments
Table 69. Pfizer Inc Business Overview
Table 70. Pfizer Inc Hypertension Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 71. Pfizer Inc Hypertension Drug Product
Table 72. Pfizer Inc Response to COVID-19 and Related Developments
Table 73. Ranbaxy Laboratories Limited Business Overview
Table 74. Ranbaxy Laboratories Limited Hypertension Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 75. Ranbaxy Laboratories Limited Hypertension Drug Product
Table 76. Ranbaxy Laboratories Limited Response to COVID-19 and Related Developments
Table 77. Sanofi S.A Business Overview
Table 78. Sanofi S.A Hypertension Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 79. Sanofi S.A Hypertension Drug Product
Table 80. Sanofi S.A Response to COVID-19 and Related Developments
Table 81. AstraZeneca Plc Business Overview
Table 82. AstraZeneca Plc Hypertension Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 83. AstraZeneca Plc Hypertension Drug Product
Table 84. AstraZeneca Plc Response to COVID-19 and Related Developments
Table 85. Johnson & Johnson Ltd Business Overview
Table 86. Johnson & Johnson Ltd Hypertension Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 87. Johnson & Johnson Ltd Hypertension Drug Product
Table 88. Johnson & Johnson Ltd Response to COVID-19 and Related Developments
Table 89. Boehringer Ingelheim Business Overview
Table 90. Boehringer Ingelheim Hypertension Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 91. Boehringer Ingelheim Hypertension Drug Product
Table 92. Boehringer Ingelheim Response to COVID-19 and Related Developments
Table 93. Merck & Co. Business Overview
Table 94. Merck & Co. Hypertension Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 95. Merck & Co. Hypertension Drug Product
Table 96. Merck & Co. Response to COVID-19 and Related Developments
Table 97. Hypertension Drug Distributors List
Table 98. Hypertension Drug Customers List
Table 99. Covid-19 Impact on Hypertension Drug Customers
LIST OF FIGURES
Figure 1. Hypertension Drug Product Picture
Figure 2. Hypertension Drug Market Segmentation
Figure 3. Research Objectives
Figure 4. Research Process
Figure 5. Data Triangulation
Figure 6. Research Approach
Figure 7. Commodity Prices-Metals Price Indices
Figure 8. Commodity Prices- Precious Metal Price Indices
Figure 9. Commodity Prices- Agricultural Raw Material Price Indices
Figure 10. Commodity Prices- Food and Beverage Price Indices
Figure 11. Commodity Prices- Fertilizer Price Indices
Figure 12. Commodity Prices- Energy Price Indices
Figure 13. G20+: Economic Policy Responses to COVID-19
Figure 14. Global Hypertension Drug Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026 (US$ Million)
Figure 15. Global Hypertension Drug Market Size, Pre-COVID-19 and Post- COVID-19, Year-over-Year Growth Rate, 2015-2026 (%)
Figure 16. Global Hypertension Drug Market Size, Quarterly Growth, 2020-2021 (%)
Figure 17. Global Hypertension Drug Market Size, Market Share by Type, 2019 VS 2020 (%)
Figure 18. Global Hypertension Drug Market Size, Market Share by Application, 2019 VS 2020 (%)
Figure 19. Global Hypertension Drug Market Size Market Share by Region, 2019 VS 2020 (%)
Figure 20. United States Composite PMI and GDP
Figure 21. Eurozone Composite PMI and GDP
Figure 22. Eurozone Core v. Periphery PMI Output Indices
Figure 23. Core v. Periphery PMI Employment Indices
Figure 24. UK Composite PMI and GDP
Figure 25. Caixin China Composite Output Index
Figure 26. Caixin China General Services Business Activity Index
Figure 27. Japan Composite Output Index
Figure 28. South Korea Manufacturing PMI
Figure 29. India Composite Output Index
Figure 30. ASEAN Manufacturing PMI
Figure 31. By Region, Asia-Pacific Hypertension Drug Market Size Market Share, 2019-2021
Figure 1. Hypertension Drug Product Picture
Figure 2. Hypertension Drug Market Segmentation
Figure 3. Research Objectives
Figure 4. Research Process
Figure 5. Data Triangulation
Figure 6. Research Approach
Figure 7. Commodity Prices-Metals Price Indices
Figure 8. Commodity Prices- Precious Metal Price Indices
Figure 9. Commodity Prices- Agricultural Raw Material Price Indices
Figure 10. Commodity Prices- Food and Beverage Price Indices
Figure 11. Commodity Prices- Fertilizer Price Indices
Figure 12. Commodity Prices- Energy Price Indices
Figure 13. G20+: Economic Policy Responses to COVID-19
Figure 14. Global Hypertension Drug Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026 (US$ Million)
Figure 15. Global Hypertension Drug Market Size, Pre-COVID-19 and Post- COVID-19, Year-over-Year Growth Rate, 2015-2026 (%)
Figure 16. Global Hypertension Drug Market Size, Quarterly Growth, 2020-2021 (%)
Figure 17. Global Hypertension Drug Market Size, Market Share by Type, 2019 VS 2020 (%)
Figure 18. Global Hypertension Drug Market Size, Market Share by Application, 2019 VS 2020 (%)
Figure 19. Global Hypertension Drug Market Size Market Share by Region, 2019 VS 2020 (%)
Figure 20. United States Composite PMI and GDP
Figure 21. Eurozone Composite PMI and GDP
Figure 22. Eurozone Core v. Periphery PMI Output Indices
Figure 23. Core v. Periphery PMI Employment Indices
Figure 24. UK Composite PMI and GDP
Figure 25. Caixin China Composite Output Index
Figure 26. Caixin China General Services Business Activity Index
Figure 27. Japan Composite Output Index
Figure 28. South Korea Manufacturing PMI
Figure 29. India Composite Output Index
Figure 30. ASEAN Manufacturing PMI
Figure 31. By Region, Asia-Pacific Hypertension Drug Market Size Market Share, 2019-2021
